- Previous Close
1.0500 - Open
1.0600 - Bid --
- Ask --
- Day's Range
1.0600 - 1.0600 - 52 Week Range
0.9860 - 4.7300 - Volume
5,147 - Avg. Volume
82,109 - Market Cap (intraday)
16.713M - Beta (5Y Monthly) -0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6300 - Earnings Date Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.80
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
www.valbiotis.comRecent News: ALVAL.PA
View MorePerformance Overview: ALVAL.PA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALVAL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALVAL.PA
View MoreValuation Measures
Market Cap
16.56M
Enterprise Value
10.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
94.77
Price/Book (mrq)
1.60
Enterprise Value/Revenue
61.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.63%
Return on Equity (ttm)
-66.90%
Revenue (ttm)
176k
Net Income Avi to Common (ttm)
-10.03M
Diluted EPS (ttm)
-0.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
11.58M
Total Debt/Equity (mrq)
55.16%
Levered Free Cash Flow (ttm)
-8.71M